[1]朱诗迪,郑 琳.经皮穿刺热消融术在肝细胞癌中的临床应用进展[J].介入放射学杂志,2022,31(12):1224-1227.
 ZHU Shidi,ZHENG Lin..Advances in clinical application of percutaneous thermal ablation for hepatocellular carcinoma[J].journal interventional radiology,2022,31(12):1224-1227.
点击复制

经皮穿刺热消融术在肝细胞癌中的临床应用进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年12
页码:
1224-1227
栏目:
综述
出版日期:
2023-01-11

文章信息/Info

Title:
Advances in clinical application of percutaneous thermal ablation for hepatocellular carcinoma
作者:
朱诗迪 郑 琳
Author(s):
ZHU Shidi ZHENG Lin.
Department of Minimally-Invasive Intervention, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province 450008, China
关键词:
【关键词】 肝细胞癌 热消融 微创介入治疗
文献标志码:
A
摘要:
【摘要】 经皮穿刺热消融术是一种微创介入治疗技术,在肝细胞癌的各临床分期治疗中均发挥着重要作用。对于早期中央型肝癌,热消融术作为根治性且微创的方法更为推荐。对于中期肝癌,有转化为根治机会者,可以通过经肝动脉化疗栓塞减瘤后再消融达到根治;对于不易转化为根治者,同步热消融联合动脉化疗栓塞可减少栓塞剂用量,相比常规动脉栓塞化疗可延长患者的无进展生存期和总生存期。对于晚期肝癌,热消融可使局部肿瘤坏死并可增加肿瘤相关抗原释放,有增敏免疫治疗效果的作用。

参考文献/References:

[1] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019:19- 28.
[2] Liu L, Zhang Q, Geng J, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates[J]. Ann Transl Med, 2020, 8: 583.
[3] Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update[J]. Oncologist, 2019, 24: e990- e1005.
[4] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36: 277- 292.
[5] Revel- Mouroz P, Otal P, Jaffro M, et al. Other non- surgical treatments for liver cancer[J]. Rep Pract Oncol Radiother, 2017, 22: 181- 192.
[6] Lucchina N, Tsetis D, Ierardi AM, et al. Current role of microwave ablation in the treatment of small hepatocellular carcinomas[J]. Ann Gastroenterol, 2016, 29: 460- 465.
[7] Yang G, Xiong Y, Sun J, et al. The efficacy of microwave ablation versus liver resection in the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta- analysis[J]. Int J Surg, 2020, 77: 85- 93.
[8] Zheng L, Zhang CH, Lin JY, et al. Comparative effectiveness of radiofrequency ablation vs. surgical resection for patients with solitary hepatocellular carcinoma smaller than 5 cm[J]. Front Oncol, 2020, 10: 399.
[9] Huang Y, Shen Q, Bai HX, et al. Comparison of radiofrequency ablation and hepatic resection for the treatment of hepatocellular carcinoma 2 cm or less[J]. J Vasc Interv Radiol, 2018, 29: 1218- 1225.
[10] Wang G, Zhang W, Tan Y, et al. The risk factors for long- term survival outcome in solitary hepatocellular carcinoma up to 2cm: propensity score matching analysis in a population cohort with a high rate of HBV infection[J]. Int J Surg, 2019, 72:1- 6.
[11] Ohmoto K,Yoshioka N,Tomiyama Y,et al. Comparison of the-rapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas[J]. J Gastroenterol Hepatol, 2009, 24: 223- 227.
[12] Wang L, Chen B, Li Z, et al. Optimal postoperative adjuvant treatment strategy for HBV- related hepatocellular carcinoma with microvascular invasion: a propensity score analysis[J]. Onco Targets Ther, 2019, 12: 1237- 1247.
[13] Ikeda K, Seki T, Umehara H, et al. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy[J]. Int J Oncol, 2007, 31: 485- 491.
[14] 谭运华.多电极转换射频消融系统治疗肝细胞癌临床和基础研究[D] .重庆:第三军医大学, 2017.
[15] Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3: 317- 325.
[16] Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, et al. Transar- terial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2017, 18: 189- 194.
[17] 王东东,李晓光. 肝癌射频消融后肿瘤残余的研究现状与进展[J]. 介入放射学杂志, 2019, 28:800- 804.
[18] 刘会永,万象新,符 孔,等. CT引导下经皮微波消融术与腹腔镜手术治疗原发性肝癌的疗效比较[J].介入放射学杂志,2019, 28:991- 995.
[19] Long J, Wang H, Zhao P, et al. Transarterial chemoembolization combined with radiofrequency ablation for solitary large hepato- cellular carcinoma ranging from 5 to 7 cm: an 8- year prospective study[J]. Abdom Radiol(NY), 2020, 45: 2736- 2747.
[20] Yan JY,Zhang JL,Wang MQ,et al. Combined transcatheter arterial chemoembolization and radiofrequency ablation in single- session for solitary hepatocellular carcinoma larger than 7 cm[J]. Asia Pac J Clin Oncol, 2018, 14: 300- 309.
[21] 张 源,翟 博.大肝癌的微创介入治疗[J]. 介入放射学杂志,2019, 28:394- 399.
[22] Chan KM, Wu TH, Cheng CH, et al. Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection[J]. Biomed J, 2019, 42: 335- 342.
[23] 吴孟超,李爱军. 应重视大肝癌的综合治疗[J]. 中华医学杂志, 2006, 86: 1657- 1659.
[24] Kim SY, An J, Lim YS, et al. MRI with liver- specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J]. JAMA Oncol, 2017, 3: 456- 463.
[25] Ichikawa T, Kumazaki T. Clinical usefulness of computed tomography arteriography and computed tomography during arterial portography for the diagnosis of early and early advanced hepatocellular carcinoma[J]. J Nippon Med Sch, 2000, 67: 105- 109.
[26] 吕天石,邹英华. 肝癌微创介入治疗进展[J]. 中国临床新医学,2020, 13:211- 215.
[27] Lee J,Shin IS,Yoon WS,et al. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malig- nancies: meta- analyses and a systematic review[J]. Radiother Oncol, 2020, 145: 63- 70.
[28] 谢小西,吕银祥,章宏欣,等. 肝动脉化疗栓塞、射频消融联合125I粒子植入治疗原发性肝癌的临床应用[J]. 介入放射学杂志, 2011, 20:863- 866.
[29] Hirooka M, Hiraoka A, Ochi H, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation: outcomes in patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2018, 210: 891- 898.
[30] Ren Y, Cao Y, Ma H, et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single- center retrospective case control study[J]. BMC Cancer, 2019, 19: 983.
[31] Bolondi L,Burroughs A,Dufour J, et al. Heterogeneity of patients with intermediate(BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis, 2012, 32: 348- 359.
[32] Kudo M, Arizumi T,Ueshima K,et al. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi’s subclassification(Kinki criteria)[J]. Dig Dis, 2015, 33: 751- 758.
[33] 王亚楠,周 翔. 早期预测经动脉化疗栓塞抵抗的研究进展[J]. 癌症进展, 2021, 19:550- 555.
[34] 刘凌晓,王建华,王小林,等. 经皮热消融同步肝动脉化疗栓塞(TACE)治疗肝癌的临床价值[J]. 复旦学报(医学版), 2015,42:1- 6.
[35] Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas[J]. Korean J Radiol, 2018, 19: 237- 246.
[36] Cun J,Xu Y,Li W,et al. Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B- related hepatocellular carcinoma[J]. J Interv Med, 2021, 4: 66- 70.
[37] Duffy AG, Ulahannan SV, Makorova- Rusher O, et al. Tremeli-mumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66: 545- 551.
[38] Kudo M. Immuno- oncology in hepatocellular carcinoma:2017 update[J]. Oncology, 2017, 93: 147- 159.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(12):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(12):333.
[3]杨岳松,汪守中,缪竞陶.介入磁共振成像技术及其临床应用[J].介入放射学杂志,2000,(02):120.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(12):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(12):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(12):974.
[7]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
 PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(12):636.
[8]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
 LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms: recent advances in research[J].journal interventional radiology,2013,(12):520.
[9]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
 YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval[J].journal interventional radiology,2014,(12):769.
[10]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
 YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma: a clinical analysis of 50 cases[J].journal interventional radiology,2013,(12):381.

备注/Memo

备注/Memo:
(收稿日期:2021- 10- 13)
(本文编辑:新 宇)
更新日期/Last Update: 2023-01-11